We are live on
!
Find out more
AA
AlphaCentric Advisors Portfolio holdings
AUM
$100M
This Fund
S&P 500
This Quarter
Est. Return
+7.21%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$166M
AUM Growth
+$16.8M
(+11%)
Cap. Flow
+$19.2M
Cap. Flow
% of AUM
11.58%
Top 10 Holdings %
Top 10 Hldgs %
22.19%
Holding
254
New
38
Increased
43
Reduced
118
Closed
26
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
United Therapeutics
UTHR
|
+$3.61M |
| 2 |
NARI
Inari Medical, Inc. Common Stock
NARI
|
+$3.1M |
| 3 |
Axsome Therapeutics
AXSM
|
+$2.73M |
| 4 |
Pfizer
PFE
|
+$2.64M |
| 5 |
TRML
Tourmaline Bio
TRML
|
+$2.15M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
IMGN
Immunogen Inc
IMGN
|
+$3.78M |
| 2 |
WBA
Walgreens Boots Alliance
WBA
|
+$3.13M |
| 3 |
ABVX
Abivax
ABVX
|
+$2.86M |
| 4 |
Ironwood Pharmaceuticals
IRWD
|
+$2.8M |
| 5 |
Amylyx Pharmaceuticals
AMLX
|
+$2.22M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 61.45% |
| 2 | Real Estate | 11.2% |
| 3 | Financials | 4.6% |
| 4 | Industrials | 3.92% |
| 5 | Technology | 2.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Immunovant
IMVT
$8.22B
| $1.23M | 0.74% |
38,000
| – | – |
|
52
AeroVironment
AVAV
$7.12B
| $1.23M | 0.74% |
+8,000
| New | +$1.07M |
|
|
RVNC
53
DELISTED
Revance Therapeutics, Inc.
RVNC
| $1.21M | 0.73% |
245,000
+25,000
| +11% | +$148K |
|
54
Intuitive Surgical
ISRG
$123B
| $1.2M | 0.72% |
3,000
-750
| -20% | -$283K |
|
55
Structure Therapeutics
GPCR
$3.35B
| $1.18M | 0.71% |
27,500
-2,500
| -8% | -$105K |
|
56
SoundHound AI
SOUN
$2.68B
| $1.18M | 0.71% |
200,000
| – | – |
|
57
Symbotic
SYM
$5.2B
| $1.13M | 0.68% |
25,000
| – | – |
|
58
Cabaletta Bio
CABA
$455M
| $1.11M | 0.67% |
+65,000
| New | +$1.4M |
|
59
Jazz Pharmaceuticals
JAZZ
$15.5B
| $1.02M | 0.62% |
8,500
-2,000
| -19% | -$245K |
|
60
Sagimet Biosciences
SGMT
$466M
| $1M | 0.6% |
+185,000
| New | +$1.33M |
|
61
Neurocrine Biosciences
NBIX
$17.4B
| $965K | 0.58% |
+7,000
| New | +$956K |
|
62
Roivant Sciences
ROIV
$24.7B
| $949K | 0.57% |
90,000
+35,000
| +64% | +$377K |
|
|
DCPH
63
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $944K | 0.57% |
+60,000
| New | +$923K |
|
64
Intuitive Machines
LUNR
$2.22B
| $938K | 0.57% |
+150,000
| New | +$713K |
|
|
VRNA
65
DELISTED
Verona Pharma
VRNA
| $901K | 0.54% |
56,000
| – | – |
|
66
Regal Rexnord
RRX
$13.8B
| $901K | 0.54% |
+5,000
| New | +$779K |
|
67
Allient
ALNT
$1.49B
| $892K | 0.54% |
+25,000
| New | +$747K |
|
68
Accuray
ARAY
$30.3M
| $865K | 0.52% |
+350,000
| New | +$937K |
|
69
AGNC Investment
AGNC
$12.7B
| $838K | 0.51% |
84,646
| – | – |
|
70
Acadia Pharmaceuticals
ACAD
$4.34B
| $832K | 0.5% |
45,000
+19,000
| +73% | +$471K |
|
71
Sanofi
SNY
$105B
| $729K | 0.44% |
+15,000
| New | +$732K |
|
72
Protagonist Therapeutics
PTGX
$8.97B
| $723K | 0.44% |
25,000
-5,000
| -17% | -$136K |
|
|
ONIT
73
Onity Group
ONIT
$338M
| $691K | 0.42% |
25,567
-2,628
| -9% | -$72.7K |
|
74
Globus Medical
GMED
$10.4B
| $671K | 0.4% |
+12,500
| New | +$672K |
|
75
Dyne Therapeutics
DYN
$3.93B
| $568K | 0.34% |
+20,000
| New | +$452K |
|
Similar funds
WCM
FCM
BIA
AGAM
E
HCM
AC
OIS
AlphaCentric Advisors's Q1 2024 Portfolio in Review
As of Q1 2024, AlphaCentric Advisors held 254 positions worth $166M, up 11% from $149M the previous quarter. Its ten largest holdings account for 22% of the portfolio.
AlphaCentric Advisors deployed $19.2M of net new capital in Q1 2024, opening 38 new positions and adding to 43 existing holdings. Its largest new stake was United Therapeutics: 16,000 shares worth $3.68M.
By sector, the portfolio is most concentrated in Healthcare at 61% of assets, up from 59% a quarter earlier, followed by Real Estate and Financials.
On the sell side, the largest reduction was Invesco NASDAQ 100 ETF, an estimated $1.72M trimmed.
- AlphaCentric Advisors's largest Q1 2024 buy was United Therapeutics: 16,000 shares worth $3.68M.
- AlphaCentric Advisors added most to Inari Medical, Inc. Common Stock in Q1 2024, an estimated $3.1M increase.
- AlphaCentric Advisors's biggest Q1 2024 reduction was Invesco NASDAQ 100 ETF, cutting an estimated $1.72M.
- AlphaCentric Advisors fully exited Immunogen Inc in Q1 2024, selling an estimated $3.78M.
- AlphaCentric Advisors's ten largest holdings make up 22% of its $166M portfolio in Q1 2024.
- AlphaCentric Advisors opened 38 new positions and closed 26 in Q1 2024.
- AlphaCentric Advisors's portfolio value rose 11% quarter-over-quarter to $166M.
Based on AlphaCentric Advisors's 13F filing for Q1 2024, filed 24 Apr 2024.